Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 3/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.38 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13390367 | 0.88 | PRF1 (0.41) | PRF1ADORA1SLC6A3MAPTKDM4E | |
| SCHEMBL12534693 | 0.88 | PRF1 (0.46) | PRF1ADORA1SLC6A3MAPTKDM4E | |
| SCHEMBL13390240 | 0.86 | PIK3CD (0.40) | PRF1ADORA1SLC6A3KDM4EALDH1A1 | |
| SCHEMBL12534753 | 0.86 | ADORA1 (0.44) | PRF1ADORA1MAPTKDM4EALDH1A1 | |
| SCHEMBL245940 | 0.86 | PRF1 (0.58) | PRF1ADORA1SLC6A3MAPTKDM4E | |
| SCHEMBL30511861 | 0.86 | PRF1 (0.58) | PRF1ADORA1SLC6A3MAPTKDM4E | |
| SCHEMBL12536061 | 0.85 | PRF1 (0.44) | PRF1ADORA1SLC6A3MAPTKDM4E | |
| SCHEMBL12536083 | 0.84 | PRF1 (0.43) | PRF1ADORA1SLC6A3MAPTKDM4E | |
| SCHEMBL12534779 | 0.83 | PRF1 (0.36) | PRF1ADORA1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL12534786 | 0.83 | ADORA1 (0.40) | PRF1ADORA1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| US-9187428-B2 | Substituted dicyanopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-17 | — | — | US | disclosed |
| US-9095582-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-8440700-B2 | Substituted aryloxazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | Bayer Schering Pharma (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210795-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | PRF1 2680/4885ADORA1 3010/4885SLC6A3 1260/4885 |
| US-20110046162-A1 | FUSED CYANOPYRIDINES AND THE USE THEREOF | TNNI3, QDPR, RYR2 | PRF1 3159/4885ADORA1 2751/4885SLC6A3 2984/4885 |
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | PPIP5K2, TPMT, PNPO | PRF1 3192/4885ADORA1 2110/4885SLC6A3 3269/4885 |
| US-20160130230-A1 | SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF | QDPR, DPYD, DDC | PRF1 2680/4885ADORA1 3010/4885SLC6A3 1260/4885 |
| US-20110130377-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | AADAC, CYP4X1, AGXT | PRF1 4674/4885ADORA1 3589/4885SLC6A3 2005/4885 |
| US-20140162981-A1 | SUBSTITUTED ARYLOXAZOLES AND THEIR USE | CYP4X1, AHR, AGXT | PRF1 4579/4885ADORA1 2450/4885SLC6A3 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.